glp receptor 1 agonists Glucagon-like peptide-1 (GLP-1) are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and #obesity. GLP-1 receptor agonists and GLP-1 and glucose-dependent insulinotropic Glucagon-like peptide 1(GLP-1) receptor agonists

This release can result in pancreatic edema, causing enzymes and other toxic substances to be trapped within the pancreas and leading to tissue damage in the pancreas and acute pancreatitis

In contrast, a pharmacological substrate is cleaved by DPP-4 ex vivo, but evidence for cleavage of the endogenous peptide in vivo may be lacking (e.g., aprotinin, BNP, -casomorphin, chorionic gonadotrophin, endomorphin-1, endomorphin-2, enterostatin, eotaxin, erythropoietin, GCSF [granulocyte colony stimulating factor], and many others)

The drugs work by mimicking GLP-1, a hormone the gut releases after eating that stimulates insulin release and suppresses glucagon to control blood sugar

GLP-1RAs hold promise as dual-action agents in IBD, offering potential benefits in metabolic control, weight loss, and disease modulation through immunological and barrier-enhancing effects